NCT00035828View on ClinicalTrials.gov

A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2001

Study Completion Date

December 31, 2002

Conditions
Pulmonary Disease, Chronic ObstructiveBronchitis, Chronic
Interventions
DRUG

ABX-IL8

Trial Locations (1)

94555

Abgenix, Fremont

Sponsors

Lead Sponsor

Abgenix
All Listed Sponsors
lead

Abgenix

INDUSTRY

NCT00035828 - A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD | Biotech Hunter | Biotech Hunter